We Build Launch-Ready Biotech Brands
Go live Day 1 with AI-optimized sites and omnichannel campaigns—built, tested, tuned.
Too often, approval comes before digital is ready. Consultants hand you a strategy deck; agencies want to run ads; internal teams are overwhelmed. Meanwhile, your launch window is closing. The first six months post-launch determine long-term success, yet most biotechs start planning too late. AIMBio bridges this gap by starting early when possible, accelerating when necessary and pressure-testing everything before Day 1.
The Person Behind AIMBio
Vika Boyko – Founder & Principal
Senior digital commercialization leader for emerging biopharma, Vika has built and run cross-functional digital & omnichannel orgs, set portfolio strategy, and partnered with CEOs, CCOs, and GMs to make Day 1 launches land.
Led digital teams from enterprise to first-launch biotech
Compressed go‑to‑market from three months to two weeks
"I started AIMBio after watching launches slip because digital arrived last. The fix: start early, pressure-test weekly, and prioritize what truly moves the needle for Day 1.
Different by Design
Track Record
Therapeutic Areas
Oncology, rare disease, neurology, immunology
Delivery Speed
Readiness audit → complete roadmap
Outcomes (Sales)
TRx growth in first full post-launch quarter
Digital Budgets
Global launch & lifecycle campaigns
Launch Day 1. Build to Scale.
AI‑powered digital launch readiness: we compress months of work so your campaigns and infrastructure are live at approval and ready to grow with your portfolio.
10x Growth
Product adoption accelerated by digital innovation
15+ Years
Building digital engines for biotech and pharma
20+ Brands
Launches across oncology, rare disease & specialty